No. of Pages: 162 | Report Code: BMIRE00027296 | Category: Life Sciences
影响全国范围内不到20万人的疾病被称为孤儿病。法布里病、庞贝病和亨特综合症都属于其中。举几个例子。支持罕见疾病新疗法的开发和评估是美国食品和药物管理局 (FDA) 的首要任务。 FDA 有权授予药物或生物制品孤儿药资格。此外，参与孤儿药分子开发的利益相关者还有资格获得以下福利：
因此，孤儿药指定药物的快速监管批准以及其他营销优势正在推动酶替代疗法市场的增长。
< p>
北美酶替代疗法市场分为美国、加拿大和墨西哥。美国酶替代疗法市场占有最大的市场份额。市场增长是由于溶酶体贮积病患病率的上升以及酶替代治疗产品的监管批准增加。静脉 (IV) 输注用于酶替代疗法 (ERT)，以治疗罕见疾病（包括戈谢综合征、法布里综合征和亨特综合征）潜在的酶缺乏。借助该酶的改良形式，ERT 可以平衡低水平的葡萄糖脑苷脂酶 (GCase)，这种酶在戈谢病、亨特病和法布里病患者体内积聚，并被这种酶分解。因此，这些罕见疾病病例的增加将需要开发新的治疗方法。例如，根据国家罕见疾病组织 (NORD) 的数据，2017 年美国患有戈谢病的人数约为 6,000 人。 2021年。根据美国国家神经疾病和中风研究所2021年8月发布的统计数据，美国估计有32,950例庞贝病病例，每40,000人中就有1人受影响。国家法布里基金会估计，截至 2020 年 5 月，美国约有 7,713 名法布里患者。因此，通过酶替代疗法治疗有限数量的罕见疾病，这推动了整个地区的市场增长。
< h3>北美酶替代疗法市场细分
北美酶替代疗法市场细分为酶类型、治疗条件、给药途径、最终用户和国家/地区。
赛诺菲；生物海洋制药公司；武田制药有限公司；艾伯维公司；杨森制药（强生服务公司）；亚力兄制药公司（阿斯塔捷利康）；之友治疗公司； Recordati SpA； Recordati SpA； CHIESI farmaceutici SpA；和辉瑞公司是北美酶替代疗法市场的领先公司。
Strategic insights for North America Enzyme Replacement Therapy involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 4,108.69 Million |
| Market Size by 2028 | US$ 6,120.01 Million |
| Global CAGR (2022 - 2028) | 6.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 酶类型
|
| Regions and Countries Covered | 北美
|
| Market leaders and key company profiles |
The regional scope of North America Enzyme Replacement Therapy refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The North America Enzyme Replacement Therapy Market is valued at US$ 4,108.69 Million in 2022, it is projected to reach US$ 6,120.01 Million by 2028.
As per our report North America Enzyme Replacement Therapy Market, the market size is valued at US$ 4,108.69 Million in 2022, projecting it to reach US$ 6,120.01 Million by 2028. This translates to a CAGR of approximately 6.9% during the forecast period.
The North America Enzyme Replacement Therapy Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Enzyme Replacement Therapy Market report:
The North America Enzyme Replacement Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Enzyme Replacement Therapy Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Enzyme Replacement Therapy Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Enzyme Replacement Therapy Market
